Cellectar BioSciences Inc. has presented its latest corporate presentation, highlighting the development of Phospholipid Drug Conjugates (PDCs). The company has validated its PDC platform, which shows promise in delivering various oncology therapeutic modalities, including radioisotopes. Notably, their advanced Phospholipid Radioconjugate (PRC), iopofosine I-131, has exceeded efficacy endpoints in a phase 2 study for Waldenstrom's macroglobulinemia $(WM)$. The company has finalized its confirmatory study design and regulatory pathway for potential FDA accelerated approval. Additionally, Cellectar has ongoing studies for other assets, such as CLR 125 and CLR 225, targeting triple-negative breast cancer and pancreatic cancer, respectively. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。